AR032451A1 - Compuesto heterociclico, un procedimiento para preparar dicho compuesto y la composicion farmaceutica que lo comprende - Google Patents
Compuesto heterociclico, un procedimiento para preparar dicho compuesto y la composicion farmaceutica que lo comprendeInfo
- Publication number
- AR032451A1 AR032451A1 ARP010101803A ARP010101803A AR032451A1 AR 032451 A1 AR032451 A1 AR 032451A1 AR P010101803 A ARP010101803 A AR P010101803A AR P010101803 A ARP010101803 A AR P010101803A AR 032451 A1 AR032451 A1 AR 032451A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- represent
- haloalkyl
- halogen
- represents hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- -1 hydroxy, methoxy Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto heterociclico con actividad antiinflamatoria que comprende la formula general 1: donde A representa un anillo de 5 miembros insaturado o parcialmente insaturado, que puede contener opcionalmente de 1 a 3 heteroátomos seleccionados de entre N, O y S, donde los dos sustituyentes aromáticos s y t están situados sobre átomos adyacentes del anillo A, y donde A puede estar además opcionalmente sustituido por uno o más sustituyentes R2; R1 representa un grupo C1-8 alquilo, C1-8 haloalquilo o -NR3R4; R2 representa C1-4 alquilo, C1-4 haloalquilo, halogeno, oxo, ciano; nitro, -CHO, -COCH3 o -COOR3; R3 representa hidrogeno, C1-8 alquilo o arilC0-8 alquilo; R4 representa hidrogeno, C1-8 alquilo, arilC1-8 alquilo, -COR5 o -COOR5; R5 representa C1-8 alquilo o C1-8 haloalquilo; X1, X2, X3 y X4 representan todos CR6, o bien uno, dos o tres de X1, X2, X3, y X4 representan nitrogeno y los restantes grupos de X1, X2, X3 y X4 representan CR6; cada R6 representan independientemente hidrogeno, halogeno, C1-3 alquilo o C1-3 alcoxi; la línea a trazos en el anillo B representa un enlace sencillo o doble; Y1 e Y4 representan independientemente CR7R7 o CO; cuando la línea a trazos representa un enlace doble Y2 e Y3 representan CR8; cuando la línea a trazos representa un enlace sencillo Y2 e Y3 representan CR8R8, y adicionalmente Y2 puede representar CO si Y1 es distinto de CO, y adicionalmente Y3 puede representar CO si Y4 es distinto de CO o bien Y3 puede representar NR9, O o S si Y4 representa CO; cada R7 representa independientemente hidrogeno, metilo o etilo; cada R8 representa independientemente hidrogeno, metilo, etilo, hidroxi, metoxi o halogeno; R9 representa hidrogeno o C1-4 alquilo; arilo en las definiciones anteriores representa fenilo o naftilo y puede estar opcionalmente sustituido por uno o más grupos elegidos de entre C1-8 alquilo, halogeno, C1-8 haloalquilo, ciano, nitro, R10OC0-8 alquilo, R10SC0-8 alquilo, -NR10R11, -NR10COR11, -COR10 o -COOR10; R10 representa hidrogeno, C1-8 alquilo o bencilo; R11 representa C1-8 alquilo o C1-8 haloalquilo; y sus sales, solvatos y prodrogas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200001138A ES2166710B1 (es) | 2000-04-25 | 2000-04-25 | Nuevos compuestos heterociclicos con actividad antiinflamatoria. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032451A1 true AR032451A1 (es) | 2003-11-12 |
Family
ID=8493411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101803A AR032451A1 (es) | 2000-04-25 | 2001-04-18 | Compuesto heterociclico, un procedimiento para preparar dicho compuesto y la composicion farmaceutica que lo comprende |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20030114456A1 (es) |
| EP (1) | EP1281709B1 (es) |
| JP (1) | JP2003531903A (es) |
| KR (1) | KR20020093952A (es) |
| AR (1) | AR032451A1 (es) |
| AT (1) | ATE289302T1 (es) |
| AU (1) | AU2001248382A1 (es) |
| BR (1) | BR0110328A (es) |
| CA (1) | CA2407418A1 (es) |
| DE (1) | DE60108953D1 (es) |
| ES (1) | ES2166710B1 (es) |
| MX (1) | MXPA02010595A (es) |
| NO (1) | NO20025101L (es) |
| WO (1) | WO2001083475A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1492773E (pt) | 2002-04-05 | 2009-05-07 | Cadila Healthcare Ltd | Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação |
| ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
| EP1832030B1 (en) * | 2004-12-23 | 2012-02-08 | ST-Ericsson SA | Low complexity blind transport format detection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026731A1 (en) * | 1993-05-13 | 1994-11-24 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| JP2000503987A (ja) * | 1996-01-26 | 2000-04-04 | ジー．ディー．サール アンド カンパニー | 炎症処置用の異項環置換イミダゾール |
| EP1288206B1 (en) * | 1996-04-12 | 2008-09-17 | G.D. Searle LLC | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors |
| ES2131015B1 (es) * | 1997-09-12 | 2000-03-01 | Almirall Prodesfarma Sa | Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas. |
| US6133292A (en) * | 1997-10-30 | 2000-10-17 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors |
| TNSN99111A1 (fr) * | 1998-06-11 | 2005-11-10 | Pfizer | Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| AR024222A1 (es) * | 1998-10-16 | 2002-09-25 | Palau Pharma Sa | Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen |
| AU4308300A (en) * | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| CA2379421A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| AU6976400A (en) * | 1999-09-08 | 2001-04-10 | Merck Frosst Canada & Co. | 1,2,3-thiadiazoles and their use as cox-2 inhibitors |
-
2000
- 2000-04-25 ES ES200001138A patent/ES2166710B1/es not_active Expired - Fee Related
-
2001
- 2001-04-18 AR ARP010101803A patent/AR032451A1/es unknown
- 2001-04-23 EP EP01921386A patent/EP1281709B1/en not_active Expired - Lifetime
- 2001-04-23 MX MXPA02010595A patent/MXPA02010595A/es unknown
- 2001-04-23 DE DE60108953T patent/DE60108953D1/de not_active Expired - Lifetime
- 2001-04-23 BR BR0110328-8A patent/BR0110328A/pt not_active IP Right Cessation
- 2001-04-23 US US10/258,471 patent/US20030114456A1/en not_active Abandoned
- 2001-04-23 AU AU2001248382A patent/AU2001248382A1/en not_active Abandoned
- 2001-04-23 KR KR1020027014345A patent/KR20020093952A/ko not_active Application Discontinuation
- 2001-04-23 CA CA002407418A patent/CA2407418A1/en not_active Abandoned
- 2001-04-23 WO PCT/ES2001/000152 patent/WO2001083475A1/es active IP Right Grant
- 2001-04-23 AT AT01921386T patent/ATE289302T1/de not_active IP Right Cessation
- 2001-04-23 JP JP2001580903A patent/JP2003531903A/ja active Pending
-
2002
- 2002-10-24 NO NO20025101A patent/NO20025101L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20025101D0 (no) | 2002-10-24 |
| DE60108953D1 (de) | 2005-03-24 |
| ATE289302T1 (de) | 2005-03-15 |
| ES2166710B1 (es) | 2004-10-16 |
| BR0110328A (pt) | 2003-01-07 |
| EP1281709B1 (en) | 2005-02-16 |
| US20030114456A1 (en) | 2003-06-19 |
| CA2407418A1 (en) | 2001-11-08 |
| KR20020093952A (ko) | 2002-12-16 |
| WO2001083475A1 (es) | 2001-11-08 |
| NO20025101L (no) | 2002-12-20 |
| AU2001248382A1 (en) | 2001-11-12 |
| MXPA02010595A (es) | 2003-03-10 |
| JP2003531903A (ja) | 2003-10-28 |
| ES2166710A1 (es) | 2003-12-01 |
| EP1281709A1 (en) | 2003-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| CO5550398A2 (es) | 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR059329A1 (es) | Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion | |
| AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR019409A1 (es) | Derivados de ftalacina utiles como inhibidores de la fosfodiestearasa 4 y composiciones farmaceuticas que incluyen dichos derivados | |
| AR053345A1 (es) | Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa | |
| AR024222A1 (es) | Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen | |
| CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
| CO5550437A2 (es) | Compuestos quimicos | |
| CY1105786T1 (el) | Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα | |
| ES2177275T3 (es) | Derivados de oxadiazolina y su uso como insecticidas. | |
| ES2184467T3 (es) | Derivados de la piperacina para la inhibicion de la replicacion del virus de la inmunodeficiencia humana. | |
| AR032428A1 (es) | Compuestos derivados de resorcinol, composicion farmaceutica, uso de los compuestos para preparar medicamentos | |
| AR032451A1 (es) | Compuesto heterociclico, un procedimiento para preparar dicho compuesto y la composicion farmaceutica que lo comprende | |
| AR066743A1 (es) | Inhibidores no nucleosidos de la transcriptasa inversa | |
| AR072103A1 (es) | Derivados de (piperazinilo con enlaces puente)-1- alcanona, su utilizacion como inhibidores de p75 y composiciones farmaceuticas que los contienen | |
| AR041720A1 (es) | Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen | |
| AR040139A1 (es) | Camptotecinas con un anillo lactona modificado | |
| AR054964A1 (es) | Un compuesto que comprende derivados de fosforamida, procedimiento para preparar dicho compuesto y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |